Abu Dhabi – M42, the UAE‑based global health pioneer powered by artificial intelligence (AI), technology, and genomics, today announced a strategic investment and partnership with UK‑based longevity biotech leader Juvenescence.
The announcement was made during Abu Dhabi Global Health Week (April 15–17, 2025), where M42 returns as a Foundational Partner for the second year in a row.
Under the terms of the collaboration, M42 and Juvenescence will co-develop a pipeline of AI‑enabled therapeutics aimed at boosting preventive care, extending healthy lifespan, and tackling life‑threatening diseases.
This move underscores M42’s commitment to supercharging its drug discovery and development capabilities following the recent launch of its Integrated Health Solutions and AI Life Sciences platforms.
The partnership brings together M42’s deep expertise in genomics, bioinformatics, biobanking, and clinical trial infrastructure with Juvenescence’s cutting‑edge AI‑driven drug discovery technology and extensive development know‑how. A Joint Steering Committee composed of senior executives from both organizations will oversee project execution, while research collaborations with leading academic institutions worldwide will further bolster M42’s biotechnology strategy in Abu Dhabi.
Commenting on the venture, Hasan Jasem Al Nowais, Managing Director and Group CEO of M42, said: “This partnership takes M42’s vision to the next level by positioning Abu Dhabi as a global hub for AI‑powered therapeutics and biomedical innovation. We’re not just innovating—we’re creating real impact on patients’ lives and the future of healthcare worldwide.”
Dr. Richard Marshall, CEO of Juvenescence, added: “We’re thrilled to join forces with M42. By merging their AI and genomics capabilities with our drug development expertise, we’ll pioneer a unique therapeutic pipeline targeting the root causes of age‑related diseases and improving global healthspan.”
Established in 2022 through the merger of G42 Healthcare and Mubadala Health, M42 operates over 480 healthcare facilities across 26 countries and employs more than 20,000 people, including renowned providers such as Cleveland Clinic Abu Dhabi and Imperial College London Diabetes Centre.
Juvenescence, a leader in AI‑enabled biotechnology, is advancing several clinical‑stage programs designed to proactively address the mechanisms of aging and promote healthy longevity.
